Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions

C Ogasawara, BD Philbrick, DC Adamson - Biomedicines, 2021 - mdpi.com
Meningiomas are the most common intracranial tumor, making up more than a third of all
primary central nervous system (CNS) tumors. They are mostly benign tumors that can be …

Meningioma: a review of clinicopathological and molecular aspects

K Huntoon, AMS Toland, S Dahiya - Frontiers in oncology, 2020 - frontiersin.org
Meningiomas are the most the common primary brain tumors in adults, representing
approximately a third of all intracranial neoplasms. They classically are found to be more …

Review of atypical and anaplastic meningiomas: classification, molecular biology, and management

TA Wilson, L Huang, D Ramanathan… - Frontiers in …, 2020 - frontiersin.org
Although the majority of meningiomas are slow-growing and benign, atypical and anaplastic
meningiomas behave aggressively with a penchant for recurrence. Standard of care …

Modern endoscopic skull base neurosurgery

R Martinez-Perez, LC Requena, RL Carrau… - Journal of neuro …, 2021 - Springer
Introduction Since the early use of the endoscopic view for treating simple intrasellar
pituitary adenomas, the skull base surgery has experienced an unprecedented revolution …

A novel patient-derived meningioma spheroid model as a tool to study and treat epithelial-to-mesenchymal transition (EMT) in meningiomas

LL van de Weijer, E Ercolano, T Zhang, M Shah… - Acta Neuropathologica …, 2023 - Springer
Meningiomas are the most common intracranial brain tumours. These tumours are
heterogeneous and encompass a wide spectrum of clinical aggressivity. Treatment options …

[HTML][HTML] A narrative review of targeted therapies in meningioma

L Kim - Chinese Clinical Oncology, 2020 - cco.amegroups.org
Meningiomas are the most common primary brain tumors constituting approximately one
third of all primary brain tumors. It affects mainly elderly population with increased incidence …

Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE

M Unterrainer, SC Kunte, LM Unterrainer… - European journal of …, 2023 - Springer
Abstract Background Somatostatin-receptor (SSTR)-targeted PET/CT provides important
clinical information in addition to standard imaging in meningioma patients.[18F] SiTATE is a …

A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma

P Kumthekar, SA Grimm, RT Aleman… - Neuro-oncology …, 2022 - academic.oup.com
Background Systemic therapies for refractory meningiomas are limited with no FDA-
approved therapeutics. Vascular endothelial growth factor (VEGF) is a signaling protein …

The long and winding road: an overview of the immunological landscape of intracranial meningiomas

GR Giammalva, L Brunasso, F Paolini, R Costanzo… - Cancers, 2022 - mdpi.com
Simple Summary The tumor microenvironment represents the essential basis for
characterizing oncological cells and supporting their growth. Along with genomic …

Clinical significance of checkpoint regulator “Programmed death ligand-1 (PD-L1)” expression in meningioma: review of the current status

S Karimi, S Mansouri, F Nassiri, S Bunda… - Journal of Neuro …, 2021 - Springer
Introduction Meningioma is the most common primary brain tumor. Most meningiomas are
benign; however, a subset of these tumors can be aggressive, presenting with early or …